Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia
In the past decade, novel targeted therapy approaches, such as BTK inhibitors and Bcl2 blockers, and innovative treatments that regulate the immune response against cancer cells, such as monoclonal antibodies, CAR-T cell therapy, and immunomodulatory molecules, have been established to provide suppo...
Main Authors: | Felice Pepe, Veronica Balatti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/2/593 |
Similar Items
-
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
by: Schieber M, et al.
Published: (2019-03-01) -
Pharmacists’ Role in Managing Patients with Chronic Lymphocytic Leukemia
by: Kevin Y. Chen, et al.
Published: (2020-03-01) -
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
by: Raquel Delgado, et al.
Published: (2021-06-01) -
HNRNPL Restrains <i>miR-155</i> Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia
by: Sara Pagotto, et al.
Published: (2019-04-01) -
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
by: Shirin Hafezi, et al.
Published: (2021-03-01)